Therapeutic Goods Administration

Australia Approves Donanemab as First Disease-Modifying Alzheimer’s Therapy

The TGA has approved the groundbreaking drug for early-stage Alzheimer’s patients, offering hope for slowing cognitive decline, though high costs and safety protocols limit access.